A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (NCT02779751)
A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group - Duplicate 2 — Springdale, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Highlands Oncology Group - Duplicate 2 — Springdale, Arkansas
- Univ of California San Francisco — San Francisco, California
- University of Colorado School of Medicine — Aurora, Colorado
- Dana Farber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Karmanos Cancer Institute — Farmington Hills, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg — Leuven,
- Centre Hospitalier Universitaire Sart Tilman — Liège,
- Centre Oscar Lambret — Lille, Hauts-de-France
- Hôpital Arnaud de Villeneuve - CHU Montpellier — Montpellier, Hérault
- Hopital Larrey — Toulouse,
- Istituto Scientifico Romagnolo - Studio e la Cura dei Tumori — Meldola, Forli
- IRCCS Ospedale San Raffaele — Milan,
- Hospital Nuestra Senora de Sonsoles — Ávila,
- Hospital San Pedro de Alcantara — Cáceres,
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Madrid Norte Sanchinarro — Madrid,
- Tri-Service General Hospital — Neihu Taipei,
- Taipei Medical University- Shuang Ho Hospital — New Taipei City,
- Chi Mei Hospital - Liouying Branch — Tainan,
- National Taiwan University Hospital — Taipei,
- Istanbul Universitesi-Cerrahpasa Cerrahpasa Tip Fakultesi Yerleskesi — Istanbul,
- Ege Universitesi Hastanesi — Izmir,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
- Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
Explore by condition: All Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.